Chromatin (DNA) Removal From Harvest Before an AAV Capture Step Greatly Improves Robustness, Purity, and Yield of the Overall Downstream Process
Presenter: Aleš Štrancar
Event: ASGCT 24th Annual Meeting
Date: May 13, 2021
Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.
Therapeutic applications of AAV-based gene therapy vectors require the process and product related impurities to be removed, as they represent serious safety threats as well as burden the economics of manufacturing.